Podcast: Inside EMA
Submitted by Anonymous (not verified) on 18 February 2026 - 9:40
Podcast: Inside EMA
Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 18 February 2026 - 9:40
Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 18 February 2026 - 8:48
Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 18 February 2026 - 8:30
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised
Vaccine Monitoring Platform: List of EMA-funded studies
Submitted by Anonymous (not verified) on 18 February 2026 - 7:32
Vaccine Monitoring Platform: List of EMA-funded studies
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 17 February 2026 - 17:00
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 2, Status: Authorised
Trulicity
Submitted by Anonymous (not verified) on 17 February 2026 - 16:21
Trulicity
ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 29 October 2025, 09:30 (CET) to 29 October 2025, 17:00 (CET)
Submitted by Anonymous (not verified) on 17 February 2026 - 16:00
ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 29 October 2025, 09:30 (CET) to 29 October 2025, 17:00 (CET)
Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 34, Status: Authorised
Submitted by Anonymous (not verified) on 17 February 2026 - 12:49
Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 34, Status: Authorised
Scientific advice and protocol assistance adopted during the CHMP meeting 26-29 January 2026
Submitted by Anonymous (not verified) on 17 February 2026 - 12:37
Scientific advice and protocol assistance adopted during the CHMP meeting 26-29 January 2026